A Symplicity Spyral™ renal denervation (RDN) system is inside a blue and green kidney.

Therapies and procedures

Symplicity™ blood pressure procedure

Lifestyle changes and medications have defined hypertension care — until now. Learn how the Symplicity™ procedure complements existing treatments to lower blood pressure.

Indications, Safety, and WarningsIndications for useThe Symplicity Spyral™ renal denervation system is indicated to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. ContraindicationsThe Symplicity Spyral™ system is contraindicated in patients with any of the following conditions:

Renal artery diameter < 3 mm or > 8 mm

Renal artery fibromuscular dysplasia (FMD)

Stented renal artery (< 3 months prior to RDN procedure)

Renal artery aneurysm

Renal artery diameter stenosis > 50%

Pregnancy

Presence of abnormal kidney (or secreting adrenal) tumor

Iliac/femoral artery stenosis precluding insertion of the catheter

Warnings and precautionsA thorough understanding of the technical principles, clinical applications, and risks associated with vascular access techniques and percutaneous transluminal catheterization in renal arteries is necessary before using this device.  The safety and efficacy of the Symplicity Spyral™ system has not been established in patients with isolated systolic hypertension or in patients with prior renal artery interventions including renal stents, renal angioplasty, or prior renal denervation. The Symplicity Spyral™ system has not yet been studied in patients who are breastfeeding, under the age of 18, or with secondary hypertension.

Avoid treatment with the Symplicity Spyral™ catheter within 5 mm of any diseased area or stent.

Implantable pacemakers (IPGs) and implantable cardioverter defibrillators (ICDs) or other active implants may be adversely affected by RF ablation. Refer to the implantable device’s Instructions for Use.

The patient’s heart rate may drop during the ablation procedure.

Proper pain medication should be administered at least 10 min before ablating renal nerves.

Potential adverse events Potential adverse events associated with use of the renal denervation device or the interventional procedures include, but are not limited to, the following conditions:

Allergic reaction to contrast

Arterial damage, including injury from energy application, dissection, or perforation

Arterial spasm or stenosis

Arterio-enteric fistula

AV fistula

Bleeding

Blood clots or embolism

Bruising

Cardiopulmonary arrest

Complications associated with medications commonly utilized during the procedure, such as narcotics, anxiolytics, or other pain or anti-vasospasm medications

Death

Deep vein thrombosis

Edema

Electrolyte imbalance

Heart rhythm disturbances, including bradycardia

Hematoma

Hematoma — retroperitoneal

Hematuria

Hypertension

Hypotension (may cause end organ hypoperfusion)

Infection

Kidney damage including renal failure or perforation

Myocardial infarction

Nausea or vomiting

Pain or discomfort

Peripheral ischemia

Pulmonary embolism

Proteinuria

Pseudoaneurysm

Radiocontrast nephropathy

Renal artery aneurysm

Skin burns from failure of the dispersive electrode pad

Stroke

Other potential adverse events that are unforeseen at this timePlease reference appropriate product  Instructions for Use and User Manual for more information regarding indications, contraindications, warnings, precautions, and potential adverse events. Caution: Federal (United States) law restricts this device to sale by or on the order of a physician.For further information, please call and/or consult Medtronic at 800-633-8766 or the Medtronic website at medtronic.com.UC202405768a EN

Renal denervation is now recommended in the hypertension guidelines published by the American College of Cardiology (ACC) and American Heart Association (AHA), and other partnering professional societies.¹

Read the guidelines

This is the turning point in hypertension care.

Current hypertension care strategies are not aIways enough to help patients achieve blood pressure control. The Symplicity™ procedure is the only interventional approach using a single catheter and radiofrequency (RF) energy to help lower blood pressure.

75% of hypertension patients in the United States do not have their blood pressure under control,² yet reducing blood pressure can significantly impact risk for cardiovascular events.

A 10 mmHg reduction in office systolic blood pressure decreases risk for³:

Major cardiovascular events by 20%
Stroke by 27%
Heart failure by 28%

The Symplicity™ procedure, which uses the Symplicity Spyral™ renal denervation system, may be able to help. Continue reading to understand:

Safety and efficacy data in patients both on and off hypertension medication
How the system works
Patient selection considerations

Watch one interventional cardiologist’s perspective:

Safety and efficacy data in patients both on and off hypertension medication

The Symplicity Spyral™ system is proven to achieve significant, safe, and sustained blood pressure reductions in the presence and absence of medications in multiple clinical trials and a real-world patient registry.^4–7

Review evidence

Results may vary.

How the system works

The Symplicity Spyral™ system is comprised of the Symplicity Spyral™ multi-electrode renal denervation catheter and the Symplicity G3™ renal denervation RF generator.

Patients whose blood pressure is difficult to control may have an overactive sympathetic nervous system. The Symplicity™ procedure aims to suppress this inappropriately elevated sympathetic drive. The Symplicity Spyral™ system offers a versatile, simple, and minimally invasive method to perform renal denervation.^§,8

View system details

This is an image of a male patient sitting near a healthcare professional who is handing him a Medtronic blood pressure brochure.

Patient selection considerations

Your patients may benefit from the Symplicity™ procedure if they have uncontrolled hypertension and are willing to undergo an interventional procedure following shared decision-making and an attempt at lifestyle modifications and medical therapy.

View detailed patient selection considerations and a summary of societal recommendations published by AHA, ACC, and the Society for Cardiovascular Angiography & Interventions (SCAI).

Explore patient selection

We‘re here for you at every turn.

Our goal is to support you and your practice as you become familiar with this therapy. We‘ve thought through everything you‘ll need to establish a Symplicity™ renal denervation program and successfully incorporate the procedure into your practice. Our support includes:

In-depth training and education
Detailed resources for patient selection and education
Expert team providing one-on-one support

Learn how we can help (open in new window)

Sign up for email to stay up to date.

We want to provide you with resources that will be the most useful as you acquaint yourself with this procedure.

Stay connected (open in new window)

Find a Symplicity™ proceduralist.

Connect your patients with a proceduralist in your area.

Find a proceduralist

Establish a Symplicity™ RDN program.

Understand the suggested framework needed to incorporate the procedure into your practice.

See the framework

Connect with a representative.

Fill out a short form if you’d like your local Medtronic rep or market development specialist to contact you.

Connect with us (open in new window)

Products

† Results may vary across patients.

‡ Includes Symplicity Spyral™ and Flex catheters.

§ One catheter size treats vessels 3–8 mm.

◊ Results of a linear multivariate mixed model (95% CI: -18.94, -15.75; p < 0.0001).

Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Published online August 14, 2025.
U.S. Department of Health and Human Services. The Surgeon General’s Call to Action to Control Hypertension. Washington, DC: U.S. Department of Health and Human Services, Office of the Surgeon General; 2020.
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. doi: 10.1016/S0140-6736(15)01225-8.
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451. doi: 10.1016/S0140-6736(20)30554-7.
Kandzari DE, Townsend R, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medication. J Am Coll Cardiol. 2023;82(19):1809–1823. doi: 10.1016/j.jacc.2023.08.045.
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10234):1401–1410. doi: 10.1016/S0140-6736(22)00455-X.
Mahfoud F, Schlaich M, Schmieder RE, et al. Long-term outcomes in ESC guideline-recommended patients for RDN from Global SYMPLICITY Registry DEFINE. EuroPCR 2025.
Symplicity Spyral™ multi-electrode renal denervation catheter instructions for use. November 18, 2023.